{"filings":[{"id":1222916,"accession_number":"0001437749-26-021446","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2026-06-23T20:27:15+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Shareholders elect three directors, approve amended equity plans at Talphera annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Marina Bozilenko, Joseph Todisco, and Mark Wan as Class III directors with over 23M votes each.","Ratified BPM LLP as independent auditor for 2026 with 31,019,362 votes for.","Advisory vote on executive compensation approved (22,874,586 for, 786,249 against).","Approved Amended 2020 Equity Incentive Plan: share reserve set at 8,561,395 shares plus up to 744,608 returning shares.","Approved Amended 2011 Employee Stock Purchase Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":68203,"accession_number":"0001437749-26-016724","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2026-05-13T20:10:24+00:00","items":["2.02","9.01"],"status":"ready","headline":"Talphera Q1 net loss $2.6M; NEPHRO CRRT study enrollment progressing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.6M ($0.04 per share) in Q1 2026, flat vs Q1 2025.","Cash and investments $21.1M as of March 31, 2026.","Combined R&D and SG&A expenses $3.9M, up from $2.9M YoY due to higher Niyad development costs.","NEPHRO CRRT study enrollment exceeded 50% milestone; completion expected in 2026.","Closed $4.1M third tranche of private placement upon hitting 35-patient enrollment milestone."],"consensus_eps_estimate":-0.0714,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103939,"accession_number":"0001437749-26-009299","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Talphera reports Q4 net loss $3.8M; NEPHRO CRRT study 50% enrolled, all 12 sites active","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $20.4M at Dec 31, 2025; net loss $3.8M ($0.06 per share) vs $1.9M ($0.07) in Q4 2024.","NEPHRO CRRT registrational study reached 35 of 70 patients (50% enrollment); all 12 sites now enrolling.","Closed $4.1M tranche of private placement upon achieving 35-patient milestone; total financing proceeds $1.6M in October 2025.","Combined R&D and SG&A expenses $3.5M in Q4 2025 vs $3.0M in Q4 2024; increase driven by Niyad development costs.","2026 cash operating expense guidance $17M-$18M, up from ~$13M in 2025, including finalizing CRRT trial and CMC/validation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103938,"accession_number":"0001437749-26-008318","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Talphera closes $4.1M third tranche of private placement, issuing shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Third closing on March 13, 2026: 639,931 shares at $0.586/share and pre-funded warrants for 6,399,316 shares at $0.585 each.","Pre-funded warrants exercisable immediately, exercise price $0.001, unlimited term.","Aggregate gross proceeds of approximately $4.1 million from the third closing.","Securities sold under Section 4(a)(2) and Regulation D; not registered under Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103937,"accession_number":"0001437749-26-008217","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Talphera receives Nasdaq bid price deficiency notice; 180 days to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on March 11, 2026 for non-compliance with minimum bid price of $1.00 per share.","Deficiency exists after 30 consecutive business days below $1.00; stock currently trades on Nasdaq Capital Market.","Company has 180 calendar days, until September 7, 2026, to regain compliance by closing at $1.00 for 10 consecutive days.","If not compliant by deadline, Talphera may seek a second 180-day period if it meets other listing standards.","Company intends to monitor bid price and evaluate options, including reverse stock split if necessary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120215,"accession_number":"0001437749-25-034446","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Talphera Q3 net loss $4.4M; cash $21.3M; Niyad study on track for H1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.4M ($0.11/sh) vs $3.4M ($0.13/sh) in Q3 2024.","Cash and investments $21.3M at Sept 30; sufficient through potential Niyad PMA approval late 2026.","Closed $17M first tranche financing led by CorMedix (CRMD); second tranche up to $29M conditional.","Five of nine NEPHRO trial sites activated; enrollment completion expected H1 2026.","Reduced 2025 cash operating expense guidance to $14-15M from $16-17M."],"consensus_eps_estimate":-0.1428,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":28000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120214,"accession_number":"0001437749-25-031731","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Talphera stockholders approve reverse stock split; company regained Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected Vincent J. Angotti, Stephen J. Hoffman, and Abhinav Jain as Class II directors.","Approved reverse stock split (1:10-1:30) to regain compliance; company already regained compliance on Oct 20, 2025.","Ratified BPM LLP as independent registered public accounting firm for FY2025.","Approved amendments to 2020 Equity Incentive Plan and 2011 Employee Stock Purchase Plan.","Advisory say-on-pay approved; future vote to be held annually."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120213,"accession_number":"0001437749-25-031468","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["3.02","8.01"],"status":"ready","headline":"Talphera raises ~$1.6M in final private placement tranches; regains Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 1,023,890 shares at $0.586/share and pre-funded warrants for 1,706,484 shares at $0.585/warrant.","Pre-funded warrants exercisable at $0.001/share with unlimited term; gross proceeds ~$1.6M.","Nasdaq notified Talphera on Oct 20, 2025 that it regained bid price compliance (closing bid ≥$1.00 for 10 consecutive days ending Oct 17, 2025).","Second and third closings of private placement occurred after certain purchasers waived conditions on Oct 21, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120212,"accession_number":"0001437749-25-031162","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Talphera appoints Joseph Todisco (CorMedix CEO) to board; grants RSUs and options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joseph Todisco appointed Class III director and compensation committee member effective Oct 14, 2025.","Todisco is CEO of CorMedix; appointment per Sept 2025 securities purchase agreement.","Granted 6,397 RSUs and options for 38,381 shares at $1.11, vesting in three equal annual installments.","CorMedix retains right to designate one board member while holding >=25% of shares from private placement.","CorMedix gets 60-day exclusive right to negotiate acquisition of Talphera after Niyad NEPHRO CRRT results, until Dec 31, 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136789,"accession_number":"0001437749-25-028787","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Talphera raises ~$17M in private placement with CorMedix; second closing tied to NEPHRO CRRT","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 25,036,360 shares at $0.55/share and pre-funded warrants for 5,845,455 shares; gross proceeds ~$17M.","Second closing of ~$12M contingent on achieving primary endpoint in NEPHRO CRRT study and VWAP >= $0.6875.","CorMedix gets board designation right if it holds >=25% of first-closing shares; 60-day exclusive negotiation right after positive NEPHRO CRRT results.","Registration rights agreement requires Talphera to file resale registration statement within 15 days after each closing.","Right of first negotiation terminates if NEPHRO CRRT study is terminated before primary endpoint or by Dec 31, 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136788,"accession_number":"0001437749-25-026938","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Talphera Q2 net loss $3.5M ($0.10/sh); NEPHRO study enrollment accelerates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["15 patients enrolled in NEPHRO registrational study; on track for completion by end of 2025, PMA submission Q1 2026.","Cash and equivalents $6.8M at June 30, 2025; closed $4.9M first tranche of $14.8M financing.","Net loss from continuing ops $3.5M vs $3.8M YoY; combined R&D/SG&A expenses $3.7M vs $4.3M.","Reduced 2025 cash operating expense guidance to $16M-$17M from prior $17M-$19M."],"consensus_eps_estimate":-0.102,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":27000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154016,"accession_number":"0001437749-25-019574","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Talphera gets 180-day extension to regain Nasdaq $1.00 bid price compliance through Dec 1, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice granting second 180-day compliance period until December 1, 2025 for minimum bid price requirement.","Common stock transferred to Nasdaq Capital Market from Global Select Market on May 30, 2025; trades under symbol TLPH.","To regain compliance, closing bid price must be at least $1.00 per share for 10 consecutive business days.","Company intends to consider a reverse stock split if necessary; warns no assurance of regaining compliance.","If not compliant by December 1, 2025, Nasdaq will delist; company may appeal to Nasdaq Hearings Panel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154015,"accession_number":"0001437749-25-016840","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Talphera Q1 2025 net loss narrows to $0.10/share; NEPHRO study reduced to 70 patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops $2.7M vs $4.0M YoY; diluted EPS loss $0.10 vs $0.16.","Cash $5.4M at March 31; adjusted to $9.8M after $4.4M net proceeds from April financing tranche.","FDA agreed to reduce NEPHRO CRRT study from 166 to 70 patients; primary endpoint powered at 90%.","Three new clinical sites activated in 2025; five more expected by mid-year for total of 13.","2025 cash operating expense guidance $17-19M, including completing registration trial by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":27000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154014,"accession_number":"0001437749-25-010729","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Talphera raises $4.9M in first closing of private placement; additional closings contingent on trial enrollment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$4.9M from first closing: 3,405,118 shares and pre-funded warrants for 4,999,316 shares at $0.586/share.","Second closing of ~$4.9M triggered by enrollment of ≥17 patients in Niyad NEPHRO CRRT study and VWAP ≥$0.7325.","Third closing of ~$4.9M triggered by enrollment of ≥35 patients in same study and VWAP ≥$0.7325.","Pre-funded warrants have $0.001 exercise price, unlimited term, and are exercisable immediately at each closing.","Registration rights agreement filed; executive officers and directors subject to 90-day lock-up after effective date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172647,"accession_number":"0001437749-25-010190","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Talphera reports Q4 2024 net loss $1.9M; FDA cuts NEPHRO study size to 70 patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA agreed to reduce NEPHRO CRRT study from 166 to 70 patients; study completion targeted by end of 2025.","Cash and investments of $8.9M at Dec 31, 2024; additional $14.8M private placement financing announced.","Q4 2024 net loss from continuing operations $1.9M ($0.07 per share) vs $4.5M ($0.25) in Q4 2023.","Combined R&D and SG&A expenses decreased to $3.0M in Q4 2024 from $4.6M in Q4 2023.","2025 cash operating expense guidance of $18M-$19M, includes costs to complete NEPHRO study."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":27000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189659,"accession_number":"0001437749-24-037242","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Talphera receives Nasdaq notice for non-compliance with $1.00 minimum bid price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Dec 6, 2024 for failure to maintain minimum bid price of $1.00 for 30 consecutive business days.","Must regain compliance by June 4, 2025; closing bid must be at least $1.00 for ten consecutive business days.","If not cured, Company may seek an additional 180-day compliance period if it meets other Nasdaq Capital Market standards.","Company states it will monitor closing bid price and evaluate options including reverse stock split to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189658,"accession_number":"0001437749-24-036376","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2024-11-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Talphera receives Nasdaq deficiency notice for stockholders' equity below $10M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity as of Sept 30, 2024 was $9.641M, below Nasdaq's $10M minimum for Global Market.","Company must submit a compliance plan by Jan 13, 2025; Nasdaq may grant up to 180-day extension.","If plan not accepted, Nasdaq will initiate delisting; Talphera can appeal to a hearings panel.","Talphera intends to submit a compliance plan but no assurance that Nasdaq will accept it.","Notice has no immediate effect on listing; common stock continues trading on Nasdaq Global Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189657,"accession_number":"0001437749-24-034907","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Talphera Q3 net loss widens to $3.4M; NEPHRO CRRT study enrollment underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.4M ($0.13/share) vs $1.4M ($0.08) in Q3 2023; cash and investments $11.1M.","Five clinical sites screening for NEPHRO CRRT study; two more expected in Q4; study completion anticipated in 2025.","Combined R&D and SG&A expenses $3.7M, up from $3.4M, driven by NEPHRO study costs.","DSUVIA divestment classified as discontinued operations; no related expenses in Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189656,"accession_number":"0001437749-24-030380","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Talphera extends deadline for second closing under securities purchase agreement to June 30, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment dated September 30, 2024 with Nantahala Management-affiliated purchasers.","Second closing deadline extended from earlier date to June 30, 2025.","If Company completes an equity financing before second closing, purchasers released from obligation to buy additional shares.","No change to other terms of original January 2024 securities purchase agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206145,"accession_number":"0001437749-24-026815","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Talphera Q2 net loss $3.8M; CMO Palmer retiring Oct 1, succeeded by Dr. Aslam","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.8M ($0.15 loss per share) vs $4.4M ($0.40 loss) in Q2 2023; cash $14.0M.","NEPHRO CRRT registrational study screening initiated; enrolling 166 patients at up to 14 U.S. sites.","Pamela Palmer, co-founder and CMO, to retire Oct 1; Dr. Shakil Aslam (current CDO) to become CMO.","Combined R&D and SG&A expenses rose to $4.3M from $4.2M year-over-year; no DSUVIA expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223195,"accession_number":"0001437749-24-021108","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Talphera stockholders elect directors, approve auditor and equity plans at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Adrian Adams and Jill Broadfoot elected as Class I directors with ~5.2M votes each.","BPM LLP ratified as independent auditor for FY 2024; 9.1M for, 0.3M against.","Advisory say-on-pay approved: 4.6M for, 0.6M against, 0.4M abstain.","Amended and restated 2020 Equity Incentive Plan and 2011 ESPP approved with >4.6M for.","Total shares represented: 9.56M of 16.99M outstanding (56.3% quorum)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223194,"accession_number":"0001437749-24-016626","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Talphera reports Q1 2024 net loss $4.0M; NEPHRO study enrollment delayed, guidance revised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops $4.0M vs income $0.1M in Q1 2023; basic EPS -$0.16.","Cash and investments $18.6M as of March 31, 2024.","NEPHRO CRRT study enrollment delayed; top-line data guidance (by Sept 30) to be revised.","Dr. Shakil Aslam appointed Chief Development Officer effective May 20, 2024.","Combined R&D and SG&A expenses decreased to $4.2M from $5.3M year-over-year."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223193,"accession_number":"0001437749-24-012568","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2024-04-19T23:59:59+00:00","items":["5.08","8.01"],"status":"ready","headline":"Talphera sets 2024 annual meeting for June 24; announces proposal deadlines","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting scheduled for June 24, 2024; record date is April 26, 2024.","Rule 14a-8 stockholder proposals must be received by April 23, 2024.","Director nominations under bylaws due by April 29, 2024.","Universal proxy notice for proxy solicitations required by April 25, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242687,"accession_number":"0001437749-24-006817","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2024-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Talphera Q4 net loss $4.5M; cash $9.4M; Niyad study enrollment imminent; $26M committed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops of $4.5M ($0.25/sh) vs $5.9M ($1.00/sh) in Q4 2022; revenues $0.3M.","Cash and investments $9.4M at Dec 31, 2023; senior debt fully repaid in Q2 2023.","Jan 2024: $26M committed capital — $8M DSUVIA royalty monetization with Xoma + $18M equity from two investors.","First patient enrollment in NEPHRO CRRT registrational study expected Q1 2024; PMA submission targeted by end 2024.","Company rebranded from AcelRx to Talphera in Jan 2024; now trades as TLPH on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242686,"accession_number":"0001437749-24-006219","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2024-03-01T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Talphera reduces board from 10 to 7; three directors resign; regains Nasdaq bid price compliance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Directors Richard Afable, Howard Rosen, and Pamela Palmer resigned effective Feb 26-28, 2024, no disagreements.","Board size reduced from ten to seven directors; committees reconstituted with continuing members.","Nasdaq notified Talphera on Feb 27 that it regained compliance with $1.00 minimum bid price rule as of Feb 26, 2024.","Pamela Palmer remains Chief Medical Officer; focus on Niyad registrational study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242685,"accession_number":"0001437749-24-001879","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2024-01-22T23:59:59+00:00","items":["1.01","2.02","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Talphera secures $26M total capital commitment: $6M upfront equity, $8M royalty monetization","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$6M upfront equity from Nantahala Capital and Rosalind Advisors; $10M additional upon positive NEPHRO trial data, $2M if stock price >=$0.92 for 5 days.","$8M non-dilutive from partial DSUVIA royalty monetization to XOMA; after specified return, Talphera shares DSUVIA royalties/milestones equally.","Preliminary cash $9.4M at Dec 31, 2023; cash operating expenses $21-23M in 2024 including NEPHRO registration trial.","Abhinav Jain of Nantahala Capital joins Board at closing.","Existing warrants amended: exercise price reduced to $0.77/share for up to 5,882,356 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242684,"accession_number":"0001437749-24-001579","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2024-01-18T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Talphera sells DSUVIA/DZUVEO royalty rights to XOMA for $8M upfront","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold rights to royalty and milestone payments from Vertical Pharma to XOMA for $8M cash.","Potential milestones up to $116.5M based on net sales; Talphera retains partial rights after stepdown.","Stepdown occurs when XOMA receives a minimum payment amount; specific amount not disclosed.","After stepdown: Talphera keeps 50% of DoD sales royalties and milestones; XOMA gets 100% non-DoD.","Agreement includes customary reps, warranties, and indemnification obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242683,"accession_number":"0001437749-24-000938","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"AcelRx rebrands to Talphera; ticker changes to TLPH Jan 10; Niyad PMA submission H2 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name changed from AcelRx Pharmaceuticals to Talphera, Inc.; new symbol TLPH effective Jan 10.","Rebranding reflects broader focus on medically supervised settings; lead candidate Niyad for dialysis circuit.","Niyad's registrational NEPHRO study to begin shortly; first patient expected Q1 2024.","PMA submission for Niyad targeted for H2 2024; product has FDA Breakthrough Designation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260071,"accession_number":"0001437749-23-030955","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AcelRx Q3 net loss $1.4M; Niyad gets FDA IDE approval, registrational study to start Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops $1.4M ($0.08/sh); revenue $0.1M from DSUVIA royalty.","Cash $13.4M at Sep 30; Oxford senior debt fully repaid in Q2 2023.","FDA IDE approval for Niyad (regional anticoagulant for dialysis); NEPHRO study to start Q4, data mid-2024.","July private placement raised $10M, with potential $16.3M additional upon milestone warrants.","Combined R&D and SG&A expenses $3.4M, down from $4.5M YoY; headcount reduction offset by Niyad costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":370000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260070,"accession_number":"0001437749-23-028683","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2023-10-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"AcelRx receives Nasdaq non-compliance notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Oct 18, 2023 for failure to maintain minimum bid price of $1.00 for 30 consecutive business days.","Must regain compliance by April 15, 2024; closing bid price must be at least $1.00 for ten consecutive business days.","If not compliant, may qualify for additional 180-day period by meeting market value standards and intending a reverse stock split.","Company will monitor closing bid price and evaluate available options to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260069,"accession_number":"0001437749-23-027971","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2023-10-10T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"AcelRx shareholders approve 1.5M share increase to 2020 equity plan; elect three directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to increase shares under the 2020 Equity Incentive Plan by 1,500,000 (for: 6,562,640; against: 486,414; abstain: 35,579).","Three Class III directors elected: Marina Bozilenko (6,746,727 for), Howard B. Rosen (6,691,709 for), Mark Wan (6,724,271 for).","Advisory vote on named executive officer compensation passed with 6,543,669 for, 510,636 against, 30,328 abstain.","Proposal to ratify Withum as auditor withdrawn after Audit Committee dismissed Withum and engaged BPM LLP effective October 2, 2023.","Total shares represented at meeting: 7,084,633 out of 16,340,118 entitled to vote (43.4% turnout)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260068,"accession_number":"0001437749-23-027772","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2023-10-05T23:59:59+00:00","items":["4.01","8.01","9.01"],"status":"ready","headline":"AcelRx dismisses auditor Withum, engages BPM; withdraws ratification proposal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed WithumSmith+Brown as independent auditor effective Oct 2, 2023; prior reports unqualified except going concern for FY 2022.","Material weakness in EPS calculation controls identified in FY 2022 was fully remediated as of June 30, 2023.","Engaged BPM LLP as new independent auditor for FY 2023; no prior consultations with BPM on accounting matters.","Withdrew auditor ratification proposal for Withum from Oct 10, 2023 annual meeting; will seek ratification of BPM at 2024 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277358,"accession_number":"0001437749-23-026612","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2023-09-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA declines to issue EUA for AcelRx's Niyad; company will pursue PMA by 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA notified AcelRx on Sept 22, 2023 it declined EUA for Niyad (nafamostat) in CRRT due to prioritization of other requests.","FDA encouraged continued clinical development of Niyad device.","AcelRx plans to initiate registrational study later in 2023 and submit PMA to FDA in 2024.","EUA was sought for use as regional anticoagulant in CRRT patients who cannot tolerate heparin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277357,"accession_number":"0001437749-23-023035","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AcelRx Q2 net loss $4.4M; raises $10M in private placement; Niyad EUA pending","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to common shareholders $4.4M ($0.40/share) vs net income $63.2M in Q2 2022.","Cash and cash equivalents $7.4M at June 30; proforma $17.4M after July private placement.","Closed $10M private placement led by Nantahala Capital, with potential $16.3M from warrants tied to milestones.","EUA for Niyad (nafamostat mesylate) submitted to FDA in April; responses awaited. Registrational study to start Q4 2023.","DSUVIA divested to Alora in April; AcelRx receives 15% royalty on commercial sales, 75% on DoD sales, up to $116.5M milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":253000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277356,"accession_number":"0001437749-23-021281","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"AcelRx reclassifies DSUVIA as discontinued in FY2022 10-K after March 2023 asset sale to Alora","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On March 12, 2023, AcelRx sold DSUVIA/DZUVEO assets to Vertical Pharmaceuticals (Alora) and classified the business as discontinued from Q1 2023.","2022 Form 10-K MD&A and financial statements restated to show DSUVIA as discontinued operations for all periods presented.","Continuing operations exclude DSUVIA; remaining business includes Zalviso, other pipeline, and collaboration revenue.","Restatement aligns with discontinued operations presentation in Q1 2023 10-Q; no other changes to 2022 10-K.","Cash, equivalents, and investments totaled $17.7M at December 31, 2022 (per restated balance sheet)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277355,"accession_number":"0001437749-23-020383","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2023-07-21T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"AcelRx raises ~$10M via private placement of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$10M from sale of 5.34M shares, pre-funded warrants for 2.01M shares, and Series A/B warrants for 7.35M shares each at $1.11 exercise price; combined price $1.36.","Closing expected July 20, 2023; placement agent H.C. Wainwright receives 5.25% fee, expense reimbursement up to $100k, and $200k if warrant exercise proceeds exceed $9.5M.","Registration rights agreement requires filing resale registration statement within 15 days, effectiveness within 90 days.","Series A/B warrants exercisable immediately, 5-year term; Series A term shortens to 45 days upon FDA EUA for Niyad; Series B term shortens upon successful registrational trial for Niyad."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295253,"accession_number":"0001437749-23-017562","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"AcelRx cures Nasdaq minimum bid price deficiency; compliance regained","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq had notified AcelRx on April 26, 2023 of non-compliance with the $1.00 minimum bid price rule.","On June 15, 2023, Nasdaq confirmed the company cured the deficiency and regained compliance.","The bid price deficiency matter is now closed with no further action required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295252,"accession_number":"0001437749-23-013597","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AcelRx Q1 net loss $8.2M; DSUVIA divestiture closed, Niyad EUA submitted","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $8.2M ($0.75/share) vs $8.7M loss in Q1 2022; cash $13.4M at March 31, 2023.","DSUVIA divestiture to Alora closed April 3; 15% royalty on commercial sales, 75% on DoD, up to $116.5M milestones.","EUA request for Niyad (nafamostat mesylate) submitted to FDA April 27; registrational study expected H2 2023.","Combined R&D and SG&A expenses $5.3M, up from $4.9M, driven by legal and Niyad costs.","Recognized $7.0M impairment on net assets held for sale from DSUVIA discontinued operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295251,"accession_number":"0001437749-23-011613","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2023-04-28T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"AcelRx receives Nasdaq deficiency notice for bid price below $1.00 per share","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice dated April 26, 2023; requires minimum $1.00 bid price for continued listing on Nasdaq Global Market.","Company has 180 calendar days (until October 23, 2023) to regain compliance by closing at $1.00+ for 10 consecutive days.","If not cured, AcelRx may seek an additional 180-day period if it meets other Nasdaq Capital Market listing standards.","Company states it will monitor bid price and evaluate options, including reverse stock split to cure deficiency.","Nasdaq has not yet initiated delisting; listing remains unchanged at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.72,"calibrated_materiality_score":0.72,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295250,"accession_number":"0001437749-23-009746","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2023-04-07T23:59:59+00:00","items":["1.02","2.01","7.01","9.01"],"status":"ready","headline":"AcelRx closes sale of DSUVIA to Alora for up to $116.5M in milestones; repays Oxford loan","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed divestment of DSUVIA to Alora Pharmaceuticals on April 3, 2023; received ~$2.7M from Aguettant and Alora at closing.","Consideration includes $1.1M upfront, 15% royalty on commercial sales, 75% on DoD sales, and up to $116.5M in milestones.","Fully repaid $5.4M Oxford loan with no prepayment penalties; company becomes debt-free after transaction.","Pro forma financials reflect removal of DSUVIA-related revenues and expenses; focus shifts to Niyad and Fedsyra pipeline.","Amended Aguettant agreements include €1.5M complementary payment and termination of certain sales milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315818,"accession_number":"0001437749-23-008621","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2023-03-30T23:59:59+00:00","items":["2.02","4.02","9.01"],"status":"ready","headline":"AcelRx restates interim 2022 financials due to EPS error; divests DSUVIA to Alora for royalties and milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-reliance on Q2 and Q3 2022 financials due to EPS calculation error (two-class method for warrants); no impact on cash, revenue, or net income.","Divests DSUVIA to Alora Pharmaceuticals; receives 15% royalty on commercial sales, 75% on DoD sales, and up to $116.5M in milestones.","Cash and short-term investments $20.8M as of Dec 31, 2022; Q4 2022 net loss $7.5M ($1.00 per share) vs $7.9M ($1.24) in Q4 2021.","Full-year 2022 DSUVIA net sales $1.8M, up 76% YoY; combined R&D and SG&A expenses $7.3M in Q4 2022.","Niyad (nafamostat) EUA submission planned for Q2 2023; Fedsyra NDA submission by end of Q2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315817,"accession_number":"0001437749-23-006898","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2023-03-16T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"AcelRx sells DSUVIA/DZUVEO assets to Vertical Pharma for up to $116.5M milestones plus royalties","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["AcelRx to sell DSUVIA/DZUVEO sufentanil tablet to Vertical Pharma; gets up to $116.5M in sales milestones and 15% net sales royalty.","75% of DoD net sales under marketing agreement; rights revert if Buyer fails to commercialize by July 1, 2023.","Aguettant amendments: EUR 1.5M payment to AcelRx, termination of sales milestones, and supply restructuring.","Terminates Catalent site readiness and commercial supply agreements; equipment to be removed from Catalent's site."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334151,"accession_number":"0001437749-22-029857","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2022-12-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"AcelRx raises ~$7.5M via registered direct offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 748,744 shares, pre-funded warrants for 2,632,898 shares, and common warrants for 4,227,052 shares at $2.22625 combined price.","Gross proceeds ~$7.5M; Cantor Fitzgerald placement agent with 7% fee.","Common warrants exercisable at $2.07 after 6 months, 6-year term, full ratchet anti-dilution with $1.00 floor.","Amended prior warrant held by purchaser to reduce exercise price to $2.07.","Closing expected on or about Dec 29, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334150,"accession_number":"0001437749-22-028437","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2022-12-05T23:59:59+00:00","items":["1.02","1.01"],"status":"ready","headline":"Patheon terminates manufacturing agreement with AcelRx; effective May 31, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Patheon provided notice on Nov 29, 2022 to terminate the MSA, originally dated Dec 12, 2012.","MSA termination effective May 31, 2024; Patheon to continue supplying product until then.","Capital Equipment Agreement between parties likewise terminates upon MSA termination.","AcelRx expects to discuss a transition plan with Patheon in the near future."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334149,"accession_number":"0001437749-22-027267","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AcelRx reports Q3 net loss of $6.9M, DSUVIA sales up 217% YoY to $0.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["DSUVIA net sales $0.5M in Q3 2022, up 217% vs Q3 2021; units sold 1,032 vs 371.","Net loss $6.9M ($0.94 per share) vs $8.4M ($1.40) in Q3 2021; cash $20.9M.","Combined R&D and SG&A expenses fell to $6.6M from $10.1M on cost reductions.","Niyad development batch produced; potential EUA submission targeted for H1 2023.","Ephedrine pre-filled syringe NDA submission expected by year-end; DSUVIA strategic partner by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":7.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":1519000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334148,"accession_number":"0001437749-22-024708","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2022-10-25T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"AcelRx effects 1:20 reverse stock split; redeems Series A Preferred for $315K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1:20 reverse stock split effective Oct 25, 2022; trading on split-adjusted basis on Nasdaq from Oct 26.","New CUSIP is 00444T 209; no fractional shares issued; cash paid in lieu.","Company redeemed all Series A Convertible Preferred Stock on Oct 12 for $315K aggregate.","Certificate of Elimination filed Oct 25 retiring the 3,000-share Series A designation.","Reverse split and preferred retirement approved by board and stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351566,"accession_number":"0001437749-22-022980","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2022-09-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"AcelRx shareholders approve reverse stock split of 1-for-10 to 1-for-30","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting held Sep 23, 2022; proposal to authorize board to effect reverse split passed.","Common shares: 53,371,108 for, 25,270,193 against; plus Series A Preferred votes included proportionally.","Board authorized to implement split at ratio from 1:10 to 1:30 within one year.","No broker non-votes; proposal was approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351565,"accession_number":"0001437749-22-020344","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2022-08-12T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"AcelRx amends bylaws to lower quorum requirement for shareholder meetings","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum changed from majority of outstanding shares to holders of at least one-third in voting power and one-third of common stock.","Separate class quorum now requires majority in voting power of that class rather than majority of shares.","Amendments approved by board on August 11, 2022, effective immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351564,"accession_number":"0001437749-22-020116","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AcelRx Q2 net income $70.7M on $84.1M debt gain; revenue $0.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $70.7M ($0.48 diluted EPS) vs net loss of $9.9M in Q2 2021, driven by $84.1M gain on extinguishment of royalty monetization liability.","Revenue $0.6M; commercial ex-DoD unit sales up 133% YoY; total DSUVIA units 10,600.","Realigned cost structure reducing headcount ~40%, generating expected annual savings of $9M.","Cash and short-term investments $27.9M as of June 30, 2022; 983 DSUVIA formulary approvals achieved.","Niyad supply chain progress; targeting Emergency Use Authorization in 2023; DZUVEO EU launch on track for Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":1012000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351563,"accession_number":"0001437749-22-018767","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","8.01","9.01"],"status":"ready","headline":"AcelRx enters $300K private placement with Lincoln Park; sets reverse split vote for Sep 23","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 3,000 Series A Preferred shares and warrant to buy 1.6M common shares at $0.2033; aggregate $300K.","Series A Preferred have 1M votes per share on reverse split proposal, voting in proportion to common stock.","Reverse stock split proposal (1:10–1:30) to be voted at Sep 23 special meeting; board recommended.","Company must convene stockholder meeting by Nov 1, 2022 for reverse split vote.","Proceeds for general corporate purposes including R&D and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-08-04T23:59:59+00:00|351563"}